Wall Street brokerages expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to announce $830,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Proteostasis Therapeutics’ earnings, with estimates ranging from $800,000.00 to $850,000.00. Proteostasis Therapeutics posted sales of $1.55 million in the same quarter last year, which suggests a negative year-over-year growth rate of 46.5%. The company is expected to issue its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year sales of $3.44 million for the current financial year, with estimates ranging from $3.39 million to $3.49 million. For the next year, analysts expect that the company will report sales of $3.52 million, with estimates ranging from $3.50 million to $3.53 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Wednesday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04). The firm had revenue of $0.84 million during the quarter, compared to analyst estimates of $1.16 million. Proteostasis Therapeutics had a negative net margin of 1,086.77% and a negative return on equity of 96.44%.
PTI traded up $0.28 during trading on Monday, hitting $7.19. The stock had a trading volume of 1,055,274 shares, compared to its average volume of 1,631,517. The stock has a market capitalization of $251.01 million, a P/E ratio of -3.06 and a beta of -3.25. Proteostasis Therapeutics has a twelve month low of $1.41 and a twelve month high of $10.38.
In related news, Director Franklin M. Berger purchased 40,000 shares of the stock in a transaction dated Friday, October 26th. The shares were acquired at an average cost of $6.75 per share, with a total value of $270,000.00. Following the purchase, the director now directly owns 266,162 shares in the company, valued at approximately $1,796,593.50. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 19.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in shares of Proteostasis Therapeutics by 0.7% in the 3rd quarter. Jennison Associates LLC now owns 3,690,138 shares of the company’s stock worth $8,893,000 after buying an additional 26,428 shares in the last quarter. Northern Trust Corp lifted its holdings in Proteostasis Therapeutics by 526.1% in the 2nd quarter. Northern Trust Corp now owns 269,451 shares of the company’s stock valued at $752,000 after purchasing an additional 226,417 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Proteostasis Therapeutics by 252.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 62,319 shares of the company’s stock valued at $174,000 after purchasing an additional 44,653 shares in the last quarter. BlackRock Inc. lifted its holdings in Proteostasis Therapeutics by 3,693.4% in the 2nd quarter. BlackRock Inc. now owns 1,807,717 shares of the company’s stock valued at $5,043,000 after purchasing an additional 1,760,063 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Proteostasis Therapeutics by 156.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 46,900 shares of the company’s stock valued at $131,000 after purchasing an additional 28,600 shares in the last quarter. Institutional investors and hedge funds own 64.57% of the company’s stock.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.